Selective decontamination in pediatric liver transplants. A randomized prospective study.
Although it has been suggested that selective decontamination of the digestive tract (SDD) decreases postoperative aerobic Gram-negative and fungal infections in orthotopic liver transplantation (OLT), no controlled trials exist in pediatric patients. This prospective, randomized controlled study of 36 pediatric OLT patients examines the effect of short-term SDD on postoperative infection and digestive tract flora. Patients were randomized into two groups. The control group received perioperative parenteral antibiotics only. The SDD group received in addition polymyxin E, tobramycin, and amphotericin B enterally and by oropharyngeal swab postoperatively until oral intake was tolerated (6 +/- 4 days). Indications for operation, preoperative status, age, and intensive care unit and hospital length of stay were no different in SDD (n = 18) and control (n = 18) groups. A total of 14 Gram-negative infections (intraabdominal abscess 7, septicemia 5, pneumonia 1, urinary tract 1) developed in the 36 patients studied. Mortality was not significantly different in the two groups. However, there were significantly fewer patients with Gram-negative infections in the SDD group: 3/18 patients (11%) vs. 11/18 patients (50%) in the control group, P < 0.001. There was also significant reduction in aerobic Gram-negative flora in the stool and pharynx in patients receiving SDD. Gram-positive and anaerobic organisms were unaffected. We conclude that short-term postoperative SDD significantly reduces Gram-negative infections in pediatric OLT patients.
Children's Hospital of Pittsburgh, Pennsylvania.
S D
SD
Smith
R J
RJ
Jackson
C J
CJ
Hannakan
R M
RM
Wadowsky
A G
AG
Tzakis
M I
MI
Rowe
D000293:Adolescent; D000666:Amphotericin B / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003141:Communicable Diseases / Q000150:complications; D004064:Digestive System / Q000382:microbiology*; D005260:Female; D006801:Humans; D007223:Infant; D016031:Liver Transplantation / Q000379:methods*; D008297:Male; D009181:Mycoses / Q000150:complications; D011113:Polymyxins / Q000627:therapeutic use; D011446:Prospective Studies; D014031:Tobramycin / Q000627:therapeutic use; D014777:Virus Diseases / Q000150:complications
D011113:Polymyxins; D000666:Amphotericin B; D014031:Tobramycin